NTRK1 and non-small cell lung carcinoma: The high dynamic of epidermal growth factor receptor (EGFR), one of the classic receptor tyrosine kinase (RTK), in NSCLC (Hirsch et al., 2003) recommended it as an attractive target for the development of small-molecule tyrosine kinase inhibitors (TKIs) to treat with NSCLC.